One-year data on immunogenicity and breakthrough infections in patients with solid tumors vaccinated against COVID-19 during systemic cancer treatment

Link to paper

van der Veldt AAM, Oosting SF, Fehrmann RSN, GeurtsvanKessel CH, van Binnendijk RS, Dingemans AC, Smit EF, Hiltermann TJN, Hartog GD, Jalving M, Westphal TT, Bhattacharya A, de Wilt F, Ernst SM, Boerma A, van Zijl L, Rimmelzwaan GF, Kvistborg P, van Els CACM, Rots NY, van Baarle D, Haanen JBAG, de Vries EGE

Patients with cancer have a higher risk of infection and severe coronavirus disease 2019 (COVID-19) despite vaccination. In the prospective multicenter VOICE trial (available at, NCT04715438), seroconversion rate after two vaccinations with mRNA-1273 was not inferior in patients treated for solid tumors with immunotherapy (cohort B; n = 131), chemotherapy (cohort C; n = 229), or chemoimmunotherapy (cohort D; n = 143) compared with controls (cohort A; n = 240). At 6 months, across cohorts, there was a similar decline in binding antibody concentration with limited Omicron BA.1 neutralizing capacity. Thereafter, participants were monitored and could receive additional COVID-19 vaccinations in the national program. Here, we present 1-year follow-up data on immunogenicity and breakthrough infections.